02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
16:28 , Jun 22, 2017 |  BC Innovations  |  Translation in Brief

Toxoplasmic indigestion

A team from the University of Michigan Medical School has discovered a new strategy and target for clearing out persistent reservoirs of the parasite Toxoplasma gondii . The approach involves disrupting lysosomal consumption of autophagosomes...
15:49 , Mar 28, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other A click chemistry-based method for delivering prodrugs to tumor cells could help treat cancer with minimal toxicity. The method has two steps: IV injection of an acetylated azidomannosamine analog that is activated by...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cathepsin B; cathepsin L (CTSL); α-synuclein (SNCA)

Neurology INDICATION: Parkinson's disease (PD) In vitro studies suggest activating cathepsin L and cathepsin B could help treat PD. In lysosomal extracts from mouse liver and brain cells, cathepsin L and cathepsin B cleaved SNCA...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

HTI-501: Additional Phase II data

Data from 36 evaluable women with moderate to severe edematous fibrosclerotic panniculopathy in the Phase II portion of a blinded, Mexican Phase I/II trial showed that subcutaneous HTI-501 met the primary endpoint of a greater...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

OxiGene preclinical data

In a mouse model of SCCHN, KGP94 significantly delayed tumor growth at doses of >=10 mg/kg vs. control mice. Data were presented at the American Association for Cancer Research meeting in San Diego. OxiGene could...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

HTI-501: Additional Phase I/II data

Interim data from 12 evaluable women with moderate to severe edematous fibrosclerotic panniculopathy in the Phase II portion of a blinded, Latin American Phase I/II trial showed that subcutaneous HTI-501 led to a median improvement...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

HTI-501: Interim Phase I/II data

Interim data from the open-label, dose-escalation Phase I portion of a blinded, placebo-controlled, Latin American Phase I/II trial in women with moderate to severe edematous fibrosclerotic panniculopathy showed that a single subcutaneous injection of HTI-501...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

HTI-501: Phase I/II started

Halozyme began a blinded, placebo-controlled, Latin American Phase I/II trial of HTI-501. The open-label, dose-escalation Phase I portion will evaluate single injections of HTI-501 in up to 48 patients and the Phase II portion will...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

OxiGene preclinical data

In vitro, KGP94 significantly inhibited cell invasion and migration of human prostate cancer cells vs. controls. KGP94 is small molecule cathepsin L inhibitor. Data were presented at the American Association for Cancer Research meeting in...